Understanding HER2 Targeted Therapy for Cancer Treatment

HER2 targeted therapy represents a significant advancement in personalized cancer treatment. 


Understanding HER2 Targeted Therapy for Cancer Treatment

HER2 targeted therapy represents a significant advancement in personalized cancer treatment. It focuses on cancers that overexpress the Human Epidermal growth factor Receptor 2 (HER2) protein, which plays a crucial role in cell growth and division. When HER2 is overexpressed, it can lead to uncontrolled cell growth and more aggressive tumor behavior. Targeted therapies are designed to specifically block the activity of this protein, helping to slow or stop cancer progression while minimizing harm to healthy cells.

What is HER2 and Why is it Important in Cancer?

HER2 is a protein found on the surface of all human cells, where it acts as a receptor. It's part of a family of receptors that receive signals from outside the cell, instructing the cell to grow, divide, and repair itself. In about 15-20% of breast cancers and a smaller percentage of other cancers, such as gastric or gastroesophageal junction cancers, the cells produce too many HER2 proteins. This condition is known as HER2-positive cancer.

An abundance of HER2 receptors means the cancer cells receive too many growth signals, leading to rapid and uncontrolled proliferation. HER2-positive cancers tend to be more aggressive and have a higher risk of recurrence compared to HER2-negative cancers. Identifying HER2 status through diagnostic testing (like immunohistochemistry or FISH tests) is critical because it determines whether a patient will benefit from HER2 targeted therapies.

How HER2 Targeted Therapy Works

Unlike traditional chemotherapy, which attacks all rapidly dividing cells, HER2 targeted therapies are precisely engineered to interfere with the specific HER2 protein. Their mechanisms of action can vary:


  • Blocking HER2 Receptors: Some therapies, known as monoclonal antibodies, attach to the HER2 receptors on the surface of cancer cells. This blocks the signals that tell the cells to grow and divide.

  • Flagging Cancer Cells: By binding to the HER2 protein, these therapies can also "flag" the cancer cells, making them more visible to the body's immune system, which can then attack and destroy them.

  • Delivering Chemotherapy Directly: A newer class of drugs, called Antibody-Drug Conjugates (ADCs), combine a monoclonal antibody with a powerful chemotherapy drug. The antibody delivers the chemotherapy directly to the HER2-positive cancer cells, minimizing damage to healthy cells.

  • Inhibiting HER2 Signaling Inside the Cell: Tyrosine kinase inhibitors (TKIs) are small molecules that enter the cell and block the internal signaling pathways activated by HER2, preventing the cell from receiving growth signals even if the external receptor is active.

Types of HER2 Targeted Therapies

Several types of HER2 targeted therapies are approved for various HER2-positive cancers:

Monoclonal Antibodies


  • Trastuzumab (Herceptin): One of the first and most widely used HER2 targeted therapies, often used in combination with chemotherapy for early and advanced HER2-positive breast and gastric cancers.

  • Pertuzumab (Perjeta): Often used in combination with trastuzumab and chemotherapy, especially for early-stage HER2-positive breast cancer and metastatic HER2-positive breast cancer. It binds to a different part of the HER2 receptor than trastuzumab, offering a more complete blockade.

  • Margetuximab (Margenza): A newer antibody that has been engineered to potentially enhance the immune system's ability to destroy cancer cells.

Antibody-Drug Conjugates (ADCs)


  • Trastuzumab emtansine (T-DM1, Kadcyla): Combines trastuzumab with a chemotherapy drug. It delivers the chemotherapy directly to HER2-positive cancer cells that have already been exposed to other HER2 therapies.

  • Trastuzumab deruxtecan (Enhertu): Another ADC that delivers a potent chemotherapy agent directly to HER2-positive cells, approved for advanced HER2-positive breast and gastric cancers.

Tyrosine Kinase Inhibitors (TKIs)


  • Lapatinib (Tykerb): A small molecule that blocks not only HER2 but also the epidermal growth factor receptor (EGFR/HER1), often used in combination with other therapies for advanced breast cancer.

  • Neratinib (Nerlynx): Used for extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab-based therapy. It also blocks HER1, HER2, and HER4.

  • Tucatinib (Tukysa): A highly selective HER2 inhibitor, approved for advanced HER2-positive breast cancer, including those with brain metastases, often used in combination with trastuzumab and capecitabine.

Cancers Treated with HER2 Targeted Therapy

The primary cancers for which HER2 targeted therapy is a standard treatment include:


  • HER2-Positive Breast Cancer: This is the most common indication, ranging from early-stage to metastatic disease.

  • HER2-Positive Gastric and Gastroesophageal Junction Cancer: Used primarily for advanced or metastatic forms of these cancers.

  • Other Cancers: Research is ongoing into the effectiveness of HER2 targeted therapies in other HER2-positive cancers, such as certain types of colorectal, lung, and ovarian cancers.

Potential Side Effects

While HER2 targeted therapies are generally better tolerated than conventional chemotherapy, they can still cause side effects. Common side effects may include:


  • Fatigue

  • Diarrhea

  • Nausea

  • Rash

  • Changes in blood counts

More serious, though less common, side effects can include:


  • Cardiac Issues: Particularly with trastuzumab, there's a risk of heart muscle damage or weakening, so heart function is monitored during treatment.

  • Lung Problems: Some ADCs can cause interstitial lung disease (inflammation of the lung tissue).

  • Liver Toxicity: Certain TKIs can affect liver function.

The specific side effects depend on the drug or combination of drugs used, and patients are closely monitored throughout their treatment.

Future Directions in HER2 Targeted Therapy

Research in HER2 targeted therapy continues to evolve rapidly. Scientists are exploring new drug combinations, novel ADCs, and next-generation TKIs to overcome resistance to existing treatments and improve outcomes. The development of therapies for low HER2 expression (HER2-low) cancers is also a promising area, potentially expanding the population who can benefit from HER2-directed approaches. These ongoing efforts aim to further personalize cancer treatment, making it more effective and less toxic for patients.